No evidence for a BRD2 promoter hypermethylation inblood leukocytes of Europeans with juvenile myoclonic epilepsy
- Schulz, H
- Ruppert, A-K
- Zara, F
- Madia, F
- Iacomino, M
- Vari, MS
- Balagura, G
- Minetti, C
- Striano, P
- Blanche, A
- Marini, C
- Guerrini, R
- Weber, YG
- Becker, F
- Lerche, H
- Kapser, C
- Schankin, CJ
- Kunz, WS
- Moller, RS
- Oliver, KL
- Bellows, ST
- Mullen, SA
- Berkovic, SF
- Scheffer, IE
- Caglayan, H
- Ozbek, U
- Hoffmann, P
- Schramm, S
- Tsortouktzidis, D
- Becker, AJ
- Sander, T
DOIAbstract
Juvenile myoclonic epilepsy (JME) is a common syndrome of genetic generalized epilepsies (GGEs). Linkage and association studies suggest that the gene encoding the bromodomain-containing protein 2 (BRD2) may increase risk of JME. The present methylation and association study followed up a recent report highlighting that the BRD2 promoter CpG island (CpG76) is differentially hypermethylated in lymphoblastoid cells from Caucasian patients with JME compared to patients with other GGE subtypes and unaffected relatives. In contrast, we found a uniform low average percentage of methylation (<4.5%) for 13 CpG76-CpGs in whole blood cells from 782 unrelated European Caucasians, including 116 JME patients, 196 patients with genetic absence epilepsies...
Add to ORKG